

2020

Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315)

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M-O, Maintz C, Bernhardt C, Losem C, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller C, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M

Lung Cancer IF 4.599 2020, in preparation

Quality of life and outcome of patients with metastatic colorectal cancer in Germany - Real-life data from the clinical Tumor Registry Colorectal Cancer (TKK)

Abstract, DGHO Oct 9 – Oct 12 2020, Basel, in preparation

Trifluridine/Tipiracil in patients with refractory metastatic colorectal cancer in clinical routine in Germany: interim results of the non-interventional study TACTIC

Göhler T, Decker T, Grundeis M, Schwaner J, Sauer A, Fichter C, Moorahrend E, Kröning H, Lipke J, Kojouharoff G, Frank M, Hogrefe C, Marschner N, Potthoff K

Abstract, DGHO Oct 9 – Oct 12 2020, Basel, in preparation

Changes in treatment of patients with multiple myeloma in Germany – results from the MYRIAM registry

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Lamberti C, Houet L, Medinger T, Jänicke M, Marschner N

Abstract DRAFT V1 DGHO Oct 9 – Oct 12 2020, Basel, in preparation

Analysis of Natural Killer cell functions in patients with Hereditary Hemochromatosis

Bönnemann V, Claus M, Butzeck B, Collette D, Bröde P, Golka K, Watzl C

EXCLI Journal 19, 430 – 441, Mar 25 2020, Dortmund

Cytoreductive treatment in “real life” – interim-analysis of 434 polycythemia vera patients in Germany

Crodel C, Jentsch-Ullrich K, Jacobasch L, Kiewe P, Kisro J, Lipke J, Prenninger S, Reiser M, Wunschel R, Hochhaus A, Heidel F

Abstract ID 214 DKK Feb 19 – Feb 22 2020, Bonn

Poster DKK Feb 19 2020, Bonn

ENLARGE-Lung: Two-Year Follow-up of Real-World Patients with Locally Advanced or Metastatic (Stage IIIB/IV) Squamos and Non-Squamos Non-Small Cell Lung Cancer (NSCLC) from a National, Prospective, Non-Interventional Study (NIS ENLARGE) of Nivolumab after Prior Chemotherapy in Germany

Gröschel A, Schumann C, Gütz S, Schulz H, Müller-Huesmann H, Schulte C, Liersch R, von der Heyde E, Wünsch V, Sebastian M

Poster 472 DKK Feb 14 – Feb 22 2020, Bonn

Dynamics in the choice of treatment for patients with multiple myeloma – results from the MYRIAM project

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosee P, Mohren M, Pfannes R, Lamberti C, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Abstract V1 2020-01-30, EHA June 2020, Frankfurt

Poster EP994, EHA 11 – 14 June 2020, Frankfurt

Untersuchung von Behandlungsrealität, Wirksamkeit und Erkrankungsverlauf von Patienten mit Multiplem Myelom in Deutschland

Knauf W, Engelhardt M, Losem C, Lipke J, Kasper C, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Poster MYRIAM DKK Feb 19 – Feb 22 2020, Bonn

2019

Behandlung der Immunthrombozyten (ITP) mit Revolade – Ergebnisse der zweiten Interimsanalyse der deutschen nicht-interventionellen Studie RISA

Meyer O, Kämpfe D, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K

Abstract Nr. A-1089-0013-00560. DGHO Oct 11 – Oct 14 2019, Berlin

Vortrag DGHO Oct 11 2019, Berlin

Die Behandlung von Myeloproliferativen Neoplasien (MPN) in Deutschland. Ein Update aus dem MPN-Register der niedergelassenen Hämatologen und Onkologen (NIHO-MPN-Register)

Steinmetz H T, Metzger S, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Schneider-Kappus W, Schmitz S

Poster P365 DGHO Oct 11 – Oct 14 2019, Berlin

Abstract Nr. A-1089-0012-00272. DGHO Oct 11 – Oct 14 2019, Berlin

MyLife: Gesundheitsbezogene Lebensqualität bei Patienten mit Multiplem Myelom – Erste Daten zur Patientenbefragung bei MYRIAM, der prospektiven, intersektoralen klinischen Registerplattform zu Behandlungsrelität, Wirksamkeit und Erkrankungsverlauf von Patienten mit Multiplem Myelom in Deutschland

Engelhardt M, Knauf W, Lipke J, Zahn M-O, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele P O, La Rosée P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Poster P713 MYRIAM DGHO Oct 11 – Oct 14 2019, Berlin

Abstract Nr. A-1089-0015-00182. DGHO Oct 11 – Oct 14 2019, Berlin

Patient-reported outcomes (PRO) on the use of ruxolitinib in myelofibrosis: data from the JAKoMo phase IV trial

Koschmieder S, Schulte C, Reiser M, Hansen R, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M

Abstract A-1089-0012-00051 Jahrestagung DGHO Oct 11 – Oct 14 2019, Berlin

Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German clinical hematology practices

Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J Löwe G, Holder I, Kiani A

Poster Jahrestagung DGHO Oct 11 – Oct 2019, Berlin

HemaSphere Journal June 2019 Volume 3 – Issue S1 – p162

Characteristics of patients with Acute Myeloid Leukaemia (AML) diagnosed in regular care: Data from the regular care AML-MDS-registry in Germany

Steinmetz HT, Aludin R, Lipke J, Liersch R, Sauer A, Tesch S, Heßling J, Schmitz S

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Poster P921 Jahrestagung DGHO Oct 11- Oct 14 2019, Berlin

Iron chelation therapy in German MDS patients with chronic iron overload under routine clinical practice (an interim analysis of EXCALIBUR study)

Metz M, Koenigsmann M, Nuckel H, von der Heyde E, Ketzler-Henkel S, Hauch U, Spohn C, Schick A, Johr C, Germing U

Poster Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Second primary malignancy (SPM) in treated and untreated patients with chronic lymphatic leukemia (CLL): an analysis of the registry of the German CLL Study Group (DCLLSG)

Fürstenau M, Stumpf T, Fink A-M, Robrecht S, Bahlo J, Maurer C, Linde H, Jacobasch L, Dörfel S, Lipke J, Aldaoud A, Fischer K, Eichhorst B, Hallek M

Abstract und Vortrag V91 Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

MyLife: Longitudinal assessment of health-related quality of life in patients with multiple myeloma in Germany – First patient-reported outcomes data from MYRIAM, the prospective, national, intersectoral cohort study for treatment and outcome of myeloma patients

Engelhardt M, Knauf W, Lipke J, Zahn MO, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele PO, La Rosee P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Lecture Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Data analysis of the thrombopoietin receptor agonist Eltrombopag efficacy in patients pretreated with corticosteroids – results of the 2nd interim analysis of the non-interventional study RISA

Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K

Abstract Nr. A-1089-0013-00560 Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

A phase 2 study of Inebilizumab plus Bendamustine versus Rituximab plus Bendamustine for the treatment of relapsed or refractory chronic lymphocytic leukemia

Spaner D, Araujo C, Andrao M, Zaucha J, Bellam N, Schulte C, Patti C, Cascavilla N, Jourdan E, Panwalkar A, Costello R, Yao NS, Elgeioushi N, Li J, Streicher K, Eck S, Marshall S, Gladstone DE

Leukemia and Lymphoma

Treatment of myeloproliferative neoplasm (MPN) in Germany. Update of the real world data from the office based MPN-registry (NIHO-MPN-registry)

Steinmetz HT, Metzger S, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Schneider-Kappus W, Schmitz S

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

CTC-conform patient self-reported determination of chemotherapy-induced peripheral neuropathy (CIPN) is feasible in daily routine practice

Losem C, Dombrowsky J, Schulte C, Bauer I, Steinmetz T

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

IO-Synthesis NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients with nivolumab in France and Germany

Dixmier A, Asselain B, Barlesi F, Debieuvre D, Audigier-Valette C, Gröschel A, Gütz S, Liersch R, Moro-Sibilot D, Müller-Huesmann H, Perol M, Raspaud C, Schulte C, Schulz H, Schumann C, Alla V, Calvet CY, Rothnie KJ, Wünsch V, Martin S

Abstract ESMO Sep 27 - Oct 01 2019, Barcelona

2019 interim analysis of the phase IV study JAKOMO: “Real-world” data on the use of ruxolitinib in myelofibrosis

Koschmieder S, Lechner A, Schulte C, Reiser M, Hansen R, Prange-Krex G, Koenigsmann M, Gröschl B, Großer S, Köhler M

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Patient-reported outcome (PRO) on the use of ruxolitinib (RUX) in myelofibrosis (MF): data from the JAKOMO phase IV trial

Koschmieder S, Schulte C, Reiser M, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M

Poster Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Real world evidence: Interim analysis of efficacy in 628 patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) treated with Nivolumab after prior chemotherapy in a national, prospective, non-interventional study (ENLARGE LUNG)

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Iron chelation therapy in German MDS patients with chronic iron overload under routine clinical practice (An interim analysis of EXCALIBUR study)

Metz M, Koenigsmann M, Nuckel H, von der Heyde E, Ketzler S, Hauch U, Spohn C, Schick A, Johr C, Germing U

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

2018

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

Marschner N, Trarbach T, Rauh J, Meyer D, Müller-Hagen S, Harde J, Dille S, Kruggel L, Jänicke M, The TMK-Group

Breast Cancer Res Treat. Springer, pp 1-12 2018, Springer Nature Switzerland

<https://link.springer.com/article/10.1007/s10549-019-05197>

Assessment of Iron Chelation Therapy in German Patients With Chronic Iron Overload Under Routine Clinical Practice (EXCALIBUR study)

Koenigsmann M, Metz M, Ketzler S, Spohn C, Schulze M, Gerhardt A, Schick A, Johr C, Germing U

Abstract EXCALIBUR Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Evidence for PTGER4, PSCA and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level.

Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Schüller V, Böhmer A, Schröder J, Gehlen J, Lordick F, Malfertheiner P, Möhler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Kupcinskis L, Brenner H, Grimminger P, Bruns C, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanas A, Keller G, Knapp M, Leja M, Kupcinskis J, Garcia-Gonzalez MA, Venerito M, Schumacher J

Carcinogenesis-Manuskript CAM4-2018-03-0711

<https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1719>

Patient self reported WHO-ECOG-Score is frequently different to the assessment by oncologists.

Losem C, Dombrowsky J, Schulte C, Koenigsmann M, Frank-Gleich S, Musch R, Steinmetz T, MVZ Onkologie/Hämatologie Neuss, Tumorzentrum Niederrhein, GP Hämatologie/Onkologie Dortmund, SP Onkologie/Hämatologie/Immunologie Hannover, GP Onkologie/Hämatologie/Gastroenterologie Halle/Saale, Praxis Onkologie/Hämatologie Berlin, GP Onkologie/Hämatologie Köln

Abstract DKK 2018 – 20170824.odt

“Real-world” data on the use of ruxolitinib in myelofibrosis: 2018 interim analysis of the prospective, non-interventional study JAKoMo

Koschmieder S, Jacobasch L, Schulte C, Geer T, Brudler O, Wehmeyer J, Klausmann M, Gröschl B, Großer S, Pahl HL

Abstract Jahrestagung DGHO Sept 28 - Oct 02 2018, Wien

Patient self-reported performance-score (PPS) is feasible in the routine ambulatory setting and predictive for successful chemotherapy

Losem C, Dombrowsky J, Schulte C, Frank-Gleich S, Musch R, Steinmetz T

Abstract Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Die Selbsteinschätzung des Performance-Status durch Patienten ist in der ambulanten Routineversorgung durchführbar und ermöglicht die Identifizierung von Patienten, die für eine Chemotherapie ungeeignet sind

Losem C, Dombrowsky J, Schulte C, Frank-Gleich S, Musch R, Steinmetz T

Poster Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

The need for transfusions in patients with lower risk myelodysplastic syndrome (MDS). Data from the regular care MDS-registry in Germany

Steinmetz HT, Toczek-Thiel J, Hellmich M, Aludin R, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S

Abstract Nr. A-0986-0016-00264 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Transfusionsbedarf von Patienten mit Niedrig-Risiko Myelodysplastischem Syndrom (MDS IPSS low + int-1) in der Regelversorgung. Daten aus dem MDS-Register der Niedergelassenen Hämatologen und Onkologen (NIHO-MDSRegister)

Steinmetz T, Toczek-Thiel J, Hellmich M, Aludin R, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S,

Poster P298 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Treatment of myeloproliferative neoplasia (MPN) in Germany. Data from the regular care MPN registry (NIHO-MPN-registry)

Steinmetz HT, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Nusch A, Schneider-Kappus W, Schmitz S

Abstract Nr. A-0986-0012-00272 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Poster P305 Jahrestagung DGHO Sept 28 – Oct 2 2018, Wien

Factors associated with the need for transfusions in patients with lower risk myelodysplastic syndrome (MDS). Data from the regular care MDS-registry in Germany

Steinmetz HT, Toczek-Thiel J, Hellmich M, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S

Abstract Nr 1155 EHA June 14 – June 17 2018, Stockholm

The prospective intersectoral national cohort study MYRIAM to study characteristics treatment and outcome of patients with multiple myeloma in Germany

Engelhardt, Knauf, Losem, Lipke, Kasper, Houet, Vannier, Jänicke, Marschner, Dechow, Einsele

Abstract EHA June 14 – June 17 2018, Stockholm

Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German clinical hematology practices

Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Löwe G, Holder IT, Kiani A

Abstract EHA June 14 – June 17 2018, Stockholm

2017

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Dec 2017, doi.org/10.1007/s12282-017-0823-7

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz T, Zahn MO, Köhler A, Engel E, Frank M, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Oct 2017 2017, doi.org/10.1007/s10549-017-4534-8

Behandlung von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) in 1° und 2°line nach vorheriger molekularer Markeranalyse mittels NGS unter realen Versorgungsbedingungen in onkologischen Schwerpunktpraxen- Zwischenergebnisse des GO-KOLORAS-Registers-.

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS Studiengruppe

Abstract P586. Jahrestagung DGHO Sept 30 – Oct 3 2017; Stuttgart

Molekulare Markeranalysen von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) und nachfolgenden Therapieentscheidungen in 1° und 2°line unter realen Versorgungsbedingungen in onkologischen Praxen.

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS-Studiengruppe

Abstract P585. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

Molekulare Testung, molekulare Veränderungen und Erstlinienbehandlung von Patienten mit Nicht-kleinzelligem Lungenkrebs (NSCLC) in Deutschland. Erste Ergebnisse der Klinischen Register Plattform CRISP (AIO-TRK-0315)

Griesinger F, Eberhardt WEE, Nusch A, Reiser M, Losem C, Ketzler-Henkel S, Zahn MO, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, de Wit M, Metzenmacher M, Waller C, Kern J, Weichert W, Sebastian M, Thomas M

Abstract. Jahrestagung DGHO Sept 30 - Oct 3 2017, Stuttgart

Myeloproliferative Neoplasien (MPN) in der Regelversorgung: Erste Daten aus dem NIHO-MPN-Register.

Steinmetz HT, Heinz M, Lipke J, Sauer A, Fries S, Schneider-Kappus W, Uhlig J, Schmitz S

Abstract P549. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.

Hurtz HJ, Tesch H, Göhler T, Hutzschenreuter U, Harde J, Kruggel L, Jänicke M, Marschner N, TMK-Group

Breast Cancer Res Treat. Springer, July 2017, doi: 10.1007/s10549-017-4365-7

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study.

Fietz T, Tesch H, Rauh J, Boller E, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

The Breast 2017; 34: 122-130

Results of the 5th interim analysis of the non-interventional MOMENT II-study: efficacy and safety of Nilotinib in newly diagnosed Ph+CML patients in chronic phase.

Tesch H, Lathan B, Sauer A, Tebbe S, Schulze M, Ulshöfer T, Lange E, Nusch A, Jäckle J, Janssen J, Rupprecht S, Meincke M, Tesanovic T

Abstract P538. Oncol Res Treat 2017; 40 (suppl3): 146

Myelodysplastic syndrome (MDS) in regular care in Germany – the oldest patients come to the fore.

Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S

Leukemia & Lymphoma 2017, <https://doi.org/10.1080/10428194.2017.1375105>

2016

Distribution of therapy regimen in patients with B-cell chronic lymphocytic leukemia (B-CLL) in 2015 in comparison to treatment strategies in 2012 based on real-world-evidence data of German oncological practices.

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P861. *Oncol Res Treat* 2016; 39 (suppl3): 258

A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data.

Koleczko S, Schäpers C, Scheffler M, Ihle M, Kostenko A, Michels S, Fischer R, Nogova L, Serke M, Kaminsky B, Benedikter J, Brümmendorf TH, Ficker JH, Lorenz J, Schulte C, Schulze-Olden S, Brandes V, Abdulla D, Ueckeroth F, Thurat M, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract V134. *Oncol Res Treat* 2016; 39 (suppl3): 32

Treatment results of 13 years CML therapy in a private office. A contribution of the German CML Alliance.

Kämpfe D, Haverkamp T, Heil G, Schulte C, Tesch H, Stein H, Die Deutsche CML-Allianz

Abstract P215. *Oncol Res Treat* 2016; 39 (suppl3): 59

Cost analysis of patients with relapsed or refractory multiple myeloma (MM) based on real-world-evidence data of German oncological practices.

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P550. *Oncol Res Treat* 2016; 39 (suppl3): 164

Analysis of potentially targetable mutations in 1056 patients with squamous cell lung cancer undergoing routine NGS-based molecular diagnostics.

Koleczko S, Scheffler M, Steinhauser S, Kostenko A, Schäpers C, Michels S, Fischer R, Brandes V, Abdulla D, Nogova L, Ueckeroth F, Thurat M, Serke M, Kaminsky B, Gerigk U, Benedikter J, Brümmendorf T, Ficker JH, Kruis W, Lorenz J, Schulte C, Schulze-Olden S, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract P. 17th World Conference on Lung Cancer Dec 4-6 2016, Wien

Prognosis of myelodysplastic syndrome (MDS) in patients in the age of 80 years and older: Data from the Regular Care MDS Registry in Germany.

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Blood 2016; 128:4333

Abstract P637. 58th Ann Meeting Am Soc Hem Dec 3-6 2016, San Diego, CA

Abstract P220. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Mutation profiling and consecutive treatment decisions under knowledge of mutation results in patients with metastatic colorectal cancer (mCRC) in real world evidence (RWE) of oncological practices – first results of the GO-KOLORAS registry study.

Lipp R, Freigang F, Brecht P, Schwaner I, Steinmetz T, Schulte C, Tiemann M

Abstract P309. Oncol Res Treat 2016; 39 (suppl3): 97

Abstract: A-813-0024-00504. Jahrestagung der DGHO, OeGHO, SSMO, SSOM, SGMO und SGHSSH Oct 14-16 2016, Leipzig

Efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase: Results of the 4th interim analysis of the non-interventional MOMENT II-study.

Sauer A, Lathan B, Tebbe S, Ulshöfer T, Lange E, Schulze M, Nusch A, Janssen J, Losem C, Meincke M, Rupprecht S, Tesch H

Abstract P211. Oncol Res Treat 2016; 39 (suppl3): 52

Abstract P211. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Three years after the start of enrolment: Current data from the prospective chronic lymphocytic leukemia (CLL)-registry of the German CLL Study Group.

Fink AM, Maurer C, Bahlo J, Kluth S, Linde H, Aldaoud A, Illmer T, Dengler J, Klausmann M, Lathan B, Al-Sawaf O, Fischer K, Wendtner CM, Eichhorst B, Hallek M

Abstract P855. Oncol Res Treat 2016; 39 (suppl3): 256

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

The relevance of the international prognostic scoring system (IPSS) for patients with myelodysplasia (MDS) at higher age.

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Abstract P220. Oncol Res Treat 2016; 39 (suppl3): 61

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Clinical characteristics and long-term outcome of myeloid/lymphoid neoplasms with PDGFRB fusion genes in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Dietz C, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lofti S, Lubert V, Maywald O, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Schmitt K, Baurmann H, Vieler T, Hofmann WK, Haferlach C, Cross NCP, Fabarius A, Reiter A, Metzgeroth G

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

Age distribution of patients with myelodysplastic syndrome (MDS) in Germany and their prognosis according to the international prognostic scoring system (IPSS): Data from the regular care MDS registry.

Steinmetz HT, Böttger I, Wahdat R, Haastert B, Sauer A, Lathan B, Germing U, Schmitz S

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

Mehr Eisen als uns gut tut – Expertenbericht: Bei der Hämochromatose ist eine unspezifische Leberwerterhöhung wichtig für die Differenzialdiagnose.

Golka K, Collette D, Claus M, Niedner H, Butzeck B

Ärztewoche 28. April 2016, SpringerMedizin, Springer Verlag Heidelberg

CONIFER – Non-interventional study to evaluate therapy monitoring during Deferasirox treatment of iron toxicity in MDS patients with transfusional iron overload in the course of treatment.

Tesch H, Bruch HR, Dencausse Y, Heßling J, Lerchenmüller C, Michel G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C

DOI 10.1159/000447035

Oncol Res Treat 2016, 39 (7-8): 424-431

Abstract. 32. Deutscher Krebskongress Feb 24-27 2016, Berlin

Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – 3rd interim analysis of the non-interventional MOMENT II-study.

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H

Abstract P114. Deutscher Krebskongress Feb 24-27 2016, Berlin

Hämochromatose – Wichtige Differentialdiagnose der unspezifischen Leberwerterhöhung. CME Zertifizierte Fortbildung.

Golka K, Collette D, Claus M, Niedner H, Butzeck B

DOI 10.1007/s40664-016-0101-0

Zbl Arbeitsmed 2016/3; 66: 171-180

Monitoring of deferasirox treatment in patients with transfusion-dependent iron toxicity due to myelodysplastic syndromes.

Tesch H, Schulte C, Bruch HR, Dencausse Y

Poster. Centrum für Hämatologie und Onkologie Bethanien 2016, Frankfurt

2015

Ergebnisse einer Interimsanalyse der nicht-interventionellen MOMENT II-Studie zur Erfassung von Wirksamkeit und Sicherheit von Nilotinib bei neu diagnostizierten Ph+ CML-Patienten in chronischer Phase im klinischen Alltag.

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H
Abstract P456. Jahrestagung DGHO Oct 9-13 2015 Berlin

Assessment of the myelodysplasia (MDS) international prognostic scoring system (IPSS) in routine care: Data from the regular care MDS registry.

Steinmetz TH, Böttger I, Sauer A, Lathan B, Germing U, Schmitz S

Abstract V606. Jahrestagung DGHO Oct 9-13 2015 Berlin

2014

Interim Results of a Phase 2 Study of MEDI-551 and Bendamustine vs. Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Gladstone DE, André M, Zaucha JM, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Streicher K, Bao H, Spaner D

Abstract P4472. 56th Ann Meeting Am Soc Hem Dec 6-9 2014, San Francisco, CA

Phase 2 Open-Label Study of MEDI 551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL.

Gladstone DE, André M, Zaucha JM, Araujo C, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Spaner D

Abstract 3028. J Clin Oncol 2014; 32 (suppl 5)

Results of an interim analysis of the non-interventional MOMENT II-study for determining efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase.

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P215. Oncol Res Treat 2014; 37 (suppl 5): 63

Hämochromatose – eine wichtige, selten gestellte Differentialdiagnose auch in der Arbeitsmedizin.

Golka K, Collette D, Müller JF, Claus M, Niedner H, Butzeck B

Umweltmed – Hygiene – Arbeitsmed 19 (2) 2014

Abstract P. Betriebl. Gesundheitsförderung/2. 54. Wiss. Jahrestagung der DGAUM April 2-4 2014, Dresden

Need of transfusion, treatment and survival of patients with Myelodysplastic Syndromes (MDS): Update of the outpatient MDS registry.

Steinmetz TH, Böttger I, Lathan B, Sauer A, Severin K, Germing U, Schmitz S

Abstract V. Jahrestagung DGHO Oct 10-14 2014 Hamburg

2013

Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – interim analysis of the non-interventional MOMENT II study.

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P217. Onkologie 2013; 36 (suppl 7): 62